SKIN.SW Cassiopea S.p.A. SIX up 9.85% pre-market 13 Mar 2026: monitor momentum and forecast

SKIN.SW stock leads Swiss small-cap movers in pre-market trade after a 9.85% jump to CHF35.70 on 13 Mar 2026. Volume is elevated at 2,756 shares versus a 50-day average of 1,818, a relative volume of 1.52. Traders cite stronger intraday momentum and a squeeze above the CHF32.00 open and CHF36.00 intraday high. We examine technicals, financials, sector context and a model forecast to frame short-term trades on SIX in Switzerland.

SKIN.SW stock pre-market move and volume

Cassiopea S.p.A. (SKIN.SW) opened at CHF32.00 and is trading 9.85% higher pre-market at CHF35.70. Intraday range shows a day low CHF32.00 and day high CHF36.00. Volume of 2,756 exceeds the daily average of 1,818, marking this a high-volume mover on SIX. This spike indicates short-term buyer interest and higher liquidity than recent sessions.

Price and technical snapshot for SKIN.SW stock

Key technicals: 50-day average price CHF34.37 and 200-day average CHF37.22. SKIN.SW is above the 50-day mean but below the 200-day mean, a mixed signal for trend-followers. Year range sits at CHF25.70 low and CHF53.00 high, so the stock still has distance from its 52-week top. Relative volume 1.52 and the move past CHF35.00 suggests momentum traders may push toward initial resistance near CHF40.00.

Fundamentals and valuation for SKIN.SW stock

Cassiopea is a clinical-stage biotech in the Healthcare sector focused on topical dermatology treatments. Latest per-share metrics show EPS -1.27 and PE -28.13, reflecting negative earnings. Book value per share is 1.50 and cash per share is 0.25. The company posts a current ratio of 1.98, and debt to equity is low at 0.00 (very small). These figures point to development-stage losses with manageable balance-sheet leverage.

Meyka AI rates SKIN.SW with a score out of 100

Meyka AI rates SKIN.SW with a score of 62.59 / 100 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector benchmarks, financial growth, key metrics and analyst consensus. Note this grade is informational only and not financial advice. For model transparency, enterprise-value metrics and cash-per-share were weighted alongside sector comparators.

Meyka AI forecast and realistic price targets for SKIN.SW stock

Meyka AI’s forecast model projects a base price target of CHF40.50 within a 6- to 12-month horizon. That implies an upside of 13.45% versus the current CHF35.70. We outline scenario targets: conservative CHF30.00 (downside -15.97%), base CHF40.50 (upside 13.45%), and bull CHF48.00 (upside 34.45%). Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for SKIN.SW stock

Primary risks are clinical trial outcomes, regulatory decisions, and continued negative EPS. Healthcare sector averages show higher profitability and PE metrics, with sector PE near 29.52, meaning SKIN.SW trades as an early-stage biotech outlier. Catalysts include trial updates for Breezula or CB-06-01, licensing news, or partnership announcements. Short-term catalysts are technical breakouts and a rising relative volume that could amplify moves.

Final Thoughts

Key takeaways for SKIN.SW stock: the pre-market 9.85% gain to CHF35.70 on 13 Mar 2026 was driven by above-average volume (2,756 vs 1,818). Technicals show a bullish tilt versus the 50-day average (CHF34.37) but resistance near the 200-day mean (CHF37.22) and psychological levels around CHF40.00. Fundamentals remain development-stage with EPS -1.27 and negative PE (-28.13). Meyka AI’s model projects a base target of CHF40.50, an implied upside of 13.45%, with a bull case to CHF48.00 and a conservative floor near CHF30.00. Traders should pair volume-driven entries with clear stop-loss rules and monitor clinical or regulatory news flow. Sources: company site and SIX market data provide primary confirmations Cassiopea website and SIX Swiss Exchange overview. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.